Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after reporting second-quarter results that came in well ahead of Wall Street estimates, driven ​by strong sales of blood thinner Eliquis and newer drugs like heart medicine ‌Camzyos and anemia treatment Reblozyl.